AUTHOR=Barbieri Maria Antonietta , Sorbara Emanuela Elisa , Battaglia Alessandro , Cicala Giuseppe , Rizzo Vincenzo , Spina Edoardo , Cutroneo Paola Maria 

TITLE=Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.808370

DOI=10.3389/fphar.2022.808370

ISSN=1663-9812

ABSTRACT=<p>Given the importance of inflammation at the onset of multiple sclerosis (MS), therapy is mainly based on the use of anti-inflammatory drugs including disease modifying therapies (DMTs). Considering the recent approval of some DMTs, pharmacovigilance becomes a fundamental tool for the acquisition of new safety data. The aim of the study was to analyze adverse drug reactions (ADRs) related to the use of drugs approved for MS. All national publicly-available aggregated ADR reports recorded from 2002 to 2020 into the Reports of Adverse Reactions of Medicines (RAM) system and all complete Sicilian data reported into the Italian spontaneous reporting system (SRS) database having as suspected drugs interferon β-1a (IFN β-1a), interferon β-1b (IFN β-1b), peginterferon β-1a (PEG-IFN β-1a), glatiramer acetate (GA), natalizumab (NTZ), fingolimod (FNG), teriflunomide (TRF), dimethyl fumarate (DMF), alemtuzumab (Alem), ocrelizumab (OCZ), or cladribine (Cladr), were collected. Descriptive analyses of national, publicly-available aggregated data and full-access regional data were performed to assess demographic characteristics and drug-related variables followed by a more in-depth analysis of all Sicilian ADRs with a case-by-case assessment and a disproportionality analysis of unexpected ADRs. A total of 13,880 national reports have been collected from 2002 to 2020: they were mainly not serious ADRs (67.9% vs. 26.1%) and related to females (71.7% <italic>vs.</italic> 26.3%) in the age group 18–65 years (76.5%). The most reported ADRs were general and administration site conditions (<italic>n</italic> = 6,565; 47.3%), followed by nervous (<italic>n</italic> = 3,090; 22.3%), skin (<italic>n</italic> = 2,763; 19.9%) and blood disorders (<italic>n</italic> = 2,180; 15.7%). Some unexpected Sicilian ADRs were shown, including dyslipidemia for FNG (<italic>n</italic> = 10; ROR 28.5, CI 14.3–59.6), NTZ (<italic>n</italic> = 5; 10.3, 4.1–25.8), and IFN β-1a (<italic>n</italic> = 4; 8.7, 3.1–24.1), abortion and alopecia for NTZ (<italic>n</italic> = 9; 208.1, 73.4–590.1; <italic>n</italic> = 3; 4.9, 1.5–15.7), and vitamin D deficiency for GA (<italic>n</italic> = 3; 121.2, 30.9–475.3). Moreover, breast cancer with DMF (<italic>n</italic> = 4, 62.8, 20.5–191.9) and hypothyroidism with Cladr (<italic>n</italic> = 3; 89.2, 25.9–307.5) were also unexpected. The reporting of drugs-related ADRs in MS were mostly reported in the literature, but some unknown ADRs were also found. However, further studies are necessary to increase the awareness about the safety profiles of new drugs on the market.</p>